Clinical feature No of cases P16 Unmethylated % P16 Methylated % P value
Patients 200 116 58% 84 42% 0.0001
Controls 25 23 92% 2 8%
P16 promoter methylation Gender
Males 128 76 59.4% 52 40.6% 0.7
Female 72 40 55.6% 32 44.4%
P16 promoter methylation with stage
CP-CML 81 60 74% 21 26% 0.0001
AP-CML 54 31 47.4% 23 42.6%
BC-CML 65 25 38.5% 40 61.5%
P16 promoter methylation with BCR-ABL transcripts
a2b2 59 31 52.5% 28 47.4%   0.5
a2b3 124 64 51.6% 60 48.3%
a2b2/ a2b3 17 11 64.7% 6 35.2%
P16 promoter methylation with type of therapy
Imatinib 200 116 58% 84 42% 0.0001
Dasatinib 10 00 00 10 100%
P16 promoter methylation and age
Age >45 71 47 66.1% 24 33.8% 0.08
Age <45 129 69 53.4% 60 46.5%
P16 promoter methylation and molecular responses
MMR 50 35 70% 15 30% 0.04
No MR 150 81 59.4% 69 46%
P16 promoter methylation and haematological responses.
MHR 30 24 80% 6 20% 0.02
Minor HR 46 26 56.5% 20 43.5%
No HR 124 66 53.2% 58 46.8%
P16 promoter methylation and Thrombocytopenia
Thrombocytopenia 100 42 42% 58 58% <0.0001
No Thrombocytopenia 100 74 74% 26 26%
Table 5: Association of P16 promoter methylation with the clinicopathological features.